Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Enveric Biosciences, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 11 | 11 | 0 |
| Shares | 24.2K | 55.0K | +30.8K (+127.4%) |
| Value | $87.7K | $106.6K | +$18.9K (+21.5%) |
New holders (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 32,149 | $62.4K | 0.00% |
| Jones Financial Companies LLLP | 1,000 | $1.88K | 0.00% |
Sold out (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Citigroup Inc | 2,276 | $8.26K |
| Bank of America Corp | 5 | $18 |